Antioxidant therapies should be effective in preventing COPD disease progression and exacerbations
Cosmetic products can only make claims related to appearance improvement
BPC-157 and TB-500 also reduce inflammation in animal studies, but as a secondary effect of their tissue-repair pathways, not as a primary mechanism
Visual Format: Side-effect and safety matrix Key Labels: Topical irritation, allergic reaction, formulation sensitivity, wound-care context, injectable route, limited safety data, peptide impurities, immunogenicity risk Suggested Layout: Create a three-column matrix: Topical products, Wound-care study context, and Injectable or compounded preparations. Under each column, list route-specific safety considerations using short, neutral labels
Congenital nonspherocytic anemia
Nature 1958